Skip to main content

Solexa Stock Falls 12 Percent After Firm Discloses Solvency Doubts Made by Accountant

NEW YORK, May 16 (GenomeWeb News) - Shares in Solexa were down 12.54 percent, or $.74, at $5.16 in mid-afternoon trading after the company today said its outside auditor had raised doubts about the firm's ability to remain in business through "at least" the end of the year.

 

Solexa said the comments, made by Ernst & Young in a March 31 SEC filing, led it to raise money through a private stock sale. In April, Solexa said it secured $32.5 million in private-equity financing led by ValueAct Capital of San Francisco.

Solexa had said it intends to use the cash to develop and launch its sequencing-by-synthesis instrument, and to repay a loan to Silicon Valley Bank.

In its annual 10-K filing with the SEC for fiscal 2004, Solexa said Ernst & Young stated the company will require additional funding if it wishes to stay in business through the end of the year. The accounting firm said Solexa's current financial position raises "substantial doubt" over its ability to remain solvent.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.